Luna Santamaría, Manuel http://orcid.org/0000-0002-3265-5381
Andersson, Daniel http://orcid.org/0000-0002-4564-6652
Parris, Toshima Z.
Helou, Khalil
Österlund, Tobias http://orcid.org/0000-0002-7870-8645
Ståhlberg, Anders http://orcid.org/0000-0003-4243-0191
Funding for this research was provided by:
Cancerfonden (2022-2080)
Barncancerfonden (MTI2019-0008)
VINNOVA (2018-00421, 2020-04141)
Stiftelsen Assar Gabrielssons Fond
Västra Götalandsregionen
Article History
Received: 19 May 2023
Accepted: 22 February 2024
First Online: 1 March 2024
Ethical statement
: All procedures related to breast cancer samples were performed in accordance with the Declaration of Helsinki and approved by the Medical Faculty Research Ethics Committee (# S164-02, Gothenburg, Sweden), where the ethical board waived the need of informed consent for retrospective biomarker analysis.
: A.S. is co-inventor of SiMSen-Seq that is patent protected (U.S. Serial No.:15/552,618). A.S. declares stock ownership and is board member in Iscaff Pharma, SiMSen Diagnostics and Tulebovaasta. All other authors declare no competing interests.